VANCOUVER, British Columbia--(BUSINESS WIRE)--Microbiome Insights, Inc., a leading provider of microbiome DNA sequencing and bioinformatic analysis, today announced the appointment of Mr. Don Enns as an independent member to its Board of Directors. Enns has been a senior executive and leader in the life sciences industry for over 30 years and brings significant company-building experience focused on providing lab testing, analytical, development, and manufacturing services to the environmental, pharmaceutical, biotechnology, and food industries globally.
"Don is a very experienced and highly-regarded business leader in the life sciences industry, and is known for building value in companies," says Mr. Malcolm Kendall, Microbiome Insights’ Chief Executive Officer. "We are delighted to have him join our Board of Directors. His operational and finance expertise, as well as his strategic insights are important for the company at this stage in its growth."
Enns is currently the Vice President and Head of Global Drug Delivery at Evonik Industries, one of the world’s leading specialty chemicals companies, with over €14 billion in annual revenue. He joined Evonik in 2016 with its acquisition of Transferra Nanoscience, where he was President and CEO. Transferra Nanosciences provided chemistry manufacturing and products to pharmaceutical and biotechnology companies, specializing in the development and manufacture of complex drug delivery systems using lipid nanoparticle science. Prior to this, Enns was President and CEO of CANTEST Ltd., a BC-headquartered company providing professional analytical and clinical services in support of the environmental, pharmaceutical, biotechnology, and food safety industries. CANTEST Ltd. was acquired by Maxxam Analytics International Corp., an OMERS owned company, in 2009.
Enns says, “Better understanding the microbiome represents a not only a significant business opportunity but also a paradigm shift in the way we monitor and treat the health of patients. I am excited to be part of Microbiome Insights and look forward to seeing the contribution we can make to this exciting field.”
The appointment of Enns coincides with the end of Dr. Pieter Cullis’s tenure as a member of the Board of Directors for Microbiome Insights. Cullis leaves to become Scientific Director of the newly established NanoMedicines Innovation Network (NMIN), a research centre focused on expanding Canada’s position as a leader in nanomedicines R&D. Cullis was a founding board member and served as a director for over four years. The company is grateful for his service and wishes him success as he guides this exciting new national centre of excellence.
About Microbiome Insights, Inc.
Microbiome Insights, Inc. is a global provider of end-to-end services for microbiome DNA sequencing and state-of-the-art bioinformatic analysis. Based in Vancouver, Canada, the company's customized suite of services enables researchers and clinicians to include microbiome analysis in studies across a range of human, animal, agricultural, and environmental applications. The multidisciplinary team of researchers and knowledge leaders at the company's helm provide access to decades of expertise in traditional sciences such as ecology, microbiology, infectious diseases, and genetics. Microbiome Insights' award-winning team is committed to providing clients with fast, dependable, cost-effective results. Learn more: microbiomeinsights.com.